Raffles Medical Group (RMG)

Broker's Calls

Broker's Digest: CapitaLand Investment, SATS, Singtel, Raffles Medical Group, MNACT

See what the analysts have to say about these counters.
DBS raises Raffles Medical Group's TP to $1.81, estimates FY2022-2023 earnings could hit record high - THE EDGE SINGAPORE

Broker's Calls

DBS raises Raffles Medical Group's TP to $1.81, estimates FY2022-2023 earnings could hit record high

As at 3.57pm, shares in Raffles Medical are trading 2 cents higher or 1.31% up at $1.55.
RHB pushes target price on Raffles Medical to $1.65 following news of further reopening of Singapore's borders - THE EDGE SINGAPORE

Broker's Calls

RHB pushes target price on Raffles Medical to $1.65 following news of further reopening of Singapore's borders

“Our new target price implies 2022F P/E of 39x, which is in line with the P/E multiple for regional (ASEAN) healthcare operators"
Imminent reopening of borders brings opportunities for Raffles Medical : RHB - THE EDGE SINGAPORE

Broker's Calls

Imminent reopening of borders brings opportunities for Raffles Medical : RHB

RHB Group Research is maintaining its ‘buy’ call and target price of $1.45 on Raffles Medical, at a 4% upside
Analysts mixed on Raffles Medical even as it appears immunised to the Covid-19 bug - THE EDGE SINGAPORE

Broker's Calls

Analysts mixed on Raffles Medical even as it appears immunised to the Covid-19 bug

The group’s PATMI of $39.4 million beat expectations of analysts from RHB and CGS-CIMB.
Raffles Medical posts 128.7% surge in 1H2021 earnings; expects to be more profitable this year - THE EDGE SINGAPORE

Results

Raffles Medical posts 128.7% surge in 1H2021 earnings; expects to be more profitable this year

Earnings of healthcare provider Raffles Medical Group surged by 128.7% to $39.4 million for 1HFY2021 ended June
'Buy' Raffles Medical, as it benefits from Singapore's reopening: analysts - THE EDGE SINGAPORE

Broker's Calls

'Buy' Raffles Medical, as it benefits from Singapore's reopening: analysts

Jaiswal is maintaining his “buy” call on the company at a revised target price of $1.35.
RHB upgrades Raffles Medical to 'buy' on return to business as usual - THE EDGE SINGAPORE

Broker's Calls

RHB upgrades Raffles Medical to 'buy' on return to business as usual

RHB analyst Shekhar Jaiswal expects the group to deliver over 25% in profit growth over the next two years.
×